metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Biología molecular del cáncer colorrectal
Información de la revista
Vol. 73. Núm. 1.
Páginas 9-17 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 73. Núm. 1.
Páginas 9-17 (enero 2003)
Acceso a texto completo
Biología molecular del cáncer colorrectal
Molecular biology of colorectal cancer
Visitas
16005
Albert Abad1
Autor para correspondencia
aabad@ns.hugtip.scs.es

Correspondencia: Dr. A. Abad. Servei d‘Oncologia Mèdica. Hospital Universitari Germans Trias i Pujol. Ctra. del Canyet s/n. 08916 Badalona. Barcelona. España.
, José Luis Manzano, Beatriz Cirauqui
Servei d‘Oncologia Mèdica.
Eva Martínez-Balibreaa
a Laboratori de Biologia Molecular del Càncer.Hospital Universitari Germans Trias i Pujol. Badalona. Barcelona. España.
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

La biología molecular del cáncer colorrectal (CCR) abarca una amplísima variedad de aspectos que van desde la conocida teoría de las etapas múltiples del desarrollo del tumor y los síndromes hereditarios hasta la aplicación al tratamiento de determinantes moleculares de sensibilidad y resistencia a citostáticos. En el cáncer hereditario cabe destacar las dos vías de la herencia, la vía supresora mediada por el gen supresor APC de la poliposis múltiple familiar y la vía mutadora mediada por la mutación en genes reparadores y conocida como síndrome de Lynch. No cabe duda del interés de los aspectos de la carcinogénesis y la herencia, pero donde mayor importancia alcanza la biología molecular del CCR en el momento actual es en su aportación al pronóstico y tratamiento de los pacientes. Genes tan importantes como el oncogén k-ras nos proporcionarán información pronóstica sobre la agresividad y capacidad de recaída y metástasis, información que podemos completar con el análisis de la inestabilidad alélica (chromosomyc imbalance) en determinados cromosomas como 8p y 18q, y también con la determinación de los títulos de expresión de timidilato sintetasa. A nuestro entender, todavía es más importante la aportación que hace al tratamiento el análisis de la expresión de genes implicados en los mecanismos de reparación del ADN, como ERCC1, y en los mecanismos de acción de citostáticos y el conocimiento de determinados polimorfismos genéticos tales como TS, UGT1A1, XRCC1, XPD, que van a modificar la sensibilidad o resistencia a determinados fármacos y que serán tratados ampliamente en esta revisión.

Plabras clave:
Polimorfismos genéticos
Cáncer colorrectal

Molecular biology in colorectal cancer (CCR) embraces a wide range of aspects from the well known theory of multiple stages in the development of a tumour and inherited syndrome, to the application on the treatment of molecular determiners of sensitivity and resistance of cytostatics. In inherited cancer we have to point out the two forms of inheritance, the suppressor way via gene suppressor APC of the familiar multiple poliposis and the mutation way via mutation in repairing genes and known as Lynch syndrome. There is no doubt about the interest of carcinogenesis aspects and inheritance but the highest importance reached by molecular biology in CCR up to now is its contribution to the prognosis and treatment of patients. Genes as important as k-ras oncogene will provide us with prognostic information about the aggresiveness and capacity of relapse and metastasis, we can complete such information with the analysis of the allelic instability (chromosomyc imbalance) in some chromosomes such as 8p and 18q and also determining levels of expression of thymydilate synthase. In our opinion it is even more important the contribution to the treatment by the analysis of the expression of genes involved in the mechanisms of repair of DNA or in the mechanisms of action of cytostatics as well as the knowledge of some genetic polimorphisms that are going to modify the sensitivity or resistance to some medicine and will be widely treated in this essay.

Key words:
Genetic polymorphisms
Colorectal cancer
El Texto completo está disponible en PDF
Bibliografía
[1.]
H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, P.A. Clarke.
Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study.
J Natl Cancer Inst, 90 (1998), pp. 675-684
[2.]
A. Font, A. Abad, M. Monzó, J.J. Sánchez, M. Guillot, J.L. Manzano, et al.
Prognostic value of k-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.
Dis Colon Rectum, 44 (2001), pp. 549-557
[3.]
J. Jen, H. Kim, S. Piantadosi, Z.F. Liu, R.C. Levitt, P. Sistonen, et al.
Allelic loss of chromosome 18q and prognosis in colorectal cancer.
N Engl J Med, 331 (1994), pp. 213-221
[4.]
O.A. Ogunbiyi, P.J. Goodfellow, K. Herfarth, G. Gagliardi, P.E. Swanson, E.H. Birnbaum, et al.
Confirmation that cromosome 18q allelic loss in colorectal cancer is a prognostic indicator.
J Clin Oncol, 16 (1998), pp. 427-433
[5.]
E. Martínez-López, A. Abad, A. Font, M. Monzó, I. Ojanguren, A. Pifarre.
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer.
Gastroenterology, 114 (1998), pp. 1180-1187
[6.]
W. Zhou, S.N. Goodman, G. Galizia, E. Lieto, F. Ferraraccio, C. Pignatelli, et al.
Counting alleles to predict recurrence of early-stage colorectal cancers.
[7.]
E. Villafranca, Y. Okruzhnov, M.A. Domínguez, J. García-Foncillas, I. Azinovic, E. Martínez, et al.
Polymorphisms of the repeat sequences in the enhancer region of the thymydilate Synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
J Clin Oncol, 19 (2001), pp. 1779-1786
[8.]
D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P.G. Johnston, I. Magnusson, et al.
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from fluorouracil -based adjuvant chemotherapy.
J Clin Oncol, 20 (2002), pp. 1721-1728
[9.]
H.J. Lenz, C.G. Leichman, K.D. Danenberg, P.V. Danenberg, S. Groshen, H. Cohen, et al.
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
J Clin Oncol, 14 (1996), pp. 176-182
[10.]
C.G. Leichman, H.J. Lenz, L. Leichman, K. Danenberg, J. Baranda, S. Groshen, et al.
Quantitation of intratumoral thymidilate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion fluorouracil and weekly leucovorin.
J Clin Oncol, 15 (1997), pp. 3223-3229
[11.]
H.J. Lenz, K. Hayashi, D. Salonga, K.D. Danenberg, P.V. Danenberg, R. Metzger, et al.
P53 point mutation and thymidylate synthase messenger mRNA levels in disseminated colorectal cancer: an analysis of response and survival.
Clin Cancer Res, 4 (1998), pp. 1243-1250
[12.]
K. Danenberg, D. Salonga, M.J. Park, C.G. Leichman, M. Johnson, R. Diasio, et al.
Dihydropyrimidine dehydrogenase and thymydilate synthase gene expression identify a high percentage of colorectal tumors responding to fluorouracil.
Proc Am Asc Clin Oncol, 17 (1998), pp. 258
[13.]
A.B. Van Kuilenburg, E.W. Muller, J. Haasjes, R. Meinsma, L. Zoetekouw, H.R. Waterham, et al.
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
Clin Can Res, 7 (2001), pp. 1149-1153
[14.]
R. Metzger, C.G. Leichman, K.D. Danenberg, P.V. Danenberg, H.J. Lenz, K. Hayashi, et al.
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric patients receiving combination cisplatin and fluorouracil chemotherapy.
J Clin Oncol, 16 (1998), pp. 309-316
[15.]
Y. Shirota, J. Stoehlmacher, J. Brabender, Y.P. Xiong, H. Uetake, K.D. Danenberg, et al.
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
J Clin Oncol, 19 (2001), pp. 4298-4304
[16.]
N. Horie, H. Aiba, K. Oguro, H. Hojo, K. Takeishi.
Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5-terminal regulatori region of the human gene for thymidylate synthase.
Cell Struc Funct, 20 (1995), pp. 191-197
[17.]
S.T. Pullarkat, V. Ghaderi, S.A. Ingles, Y. Xiong, P. Chen, J. Stoehlmacher, et al.
Human thymidylate synthase gene polymorphism determines response to 5-FU chemotherapy.
Proc Am Asc Clin Oncol, 19 (2000), pp. 942
[18.]
S.T. Pullarkat, J. Stoehlmacher, V. Ghaderi, Y.P. Xiong, S.A. Ingles, A. Sherrod, et al.
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.
Pharmacogenomics J, 1 (2001), pp. 65-70
[19.]
S. Marsh, J.A. McKay, J. Cassidy, H.L. McLeod.
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
Int J Oncol, 19 (2001), pp. 383-386
[20.]
D.J. Park, J. Stoehlmacher, W. Zhang, S. Groshen, H. Lenz, et al.
Human thymidylate synthase polimorphism determines response to capecitabina chemotherapy in advanced colorectal cancer.
Proc Am Asc Clin Oncol, 20 (2001), pp. 514
[21.]
A. Abad, M. Margeli, E. Martínez, A. Barnadas, M. Guillot, A. Font, et al.
Loss of predictive value of thymidylate synthase gene polymorphism for 5-FU based polychemotherapy response.
Proc Am Asc Clin Oncol, 20 (2001), pp. 3284
[22.]
Y. Ando, H. Saka, M. Ando, T. Sawa, K. Muro, H. Ueoka, et al.
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Cancer Res, 60 (2000), pp. 6921-6926
[23.]
J. Stoehlmacher, V. Ghaderi, S. Groshen, D. Tsao-Wei, H.J. Lenz.
The role of the XRCC1 gene in platinum based treatment of advanced colorectal cancer.
Proc Am Asc Cancer Res, 42 (2001), pp. 3750
[24.]
J. Stoehlmacher, V. Ghaderi, S. Iobal, S. Groshen, D. Tsao-Wei, D. Park, et al.
A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.
Anticancer Res, 21 (2001), pp. 3075-3079
[25.]
R.M. Lunn, K.J. Helzlsouer, R. Parshad, D.M. Umbach, E.L. Harris, K.K. Sanford, et al.
A XPD polymorphism effects on DNA repair proficiency.
Carcinogenesis, 21 (2000), pp. 551-555
[26.]
M.R. Spitz, X. Wu, Y. Wang, L.E. Wang, S. Shete, C.I. Amos, et al.
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.
Cancer Res, 61 (2001), pp. 1354-1357
[27.]
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients
Copyright © 2003. Asociación Española de Cirujanos
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos